Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMINA: Dasatinib and Quercetin for MCI and Mobility in Aging
NCT05422885Phase 2Completed
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in Mild Cognitive Impairment (MCI), Alzheimer's disease (AD). Started May 2022; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05422885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422885.